We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
- Authors
Novotna, A; Mares, J; Ratcliffe, S; Novakova, I; Vachova, M; Zapletalova, O; Gasperini, C; Pozzilli, C; Cefaro, L; Comi, G; Rossi, P; Ambler, Z; Stelmasiak, Z; Erdmann, A; Montalban, X; Klimek, A; Davies, P; Sativex Spasticity Study Group
- Abstract
Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.
- Publication
European journal of neurology, 2011, Vol 18, Issue 9, p1122
- ISSN
1468-1331
- Publication type
Journal Article
- DOI
10.1111/j.1468-1331.2010.03328.x